Atezolizumab plus carboplatin plus paclitaxel plus bevacizumab (ACPB) regimen significantly improved the PFS and OS in advanced NSCLC patients, regardless of PD‐L1 expression and EGFR or ALK genetic alteration status.308. Here, EGFR is linked to non-small cell lung carcinoma.